Injecting CpG-ODN to enhance immune response against advanced solid tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the safety and clinical effects of injecting CpG-ODN directly into tumors, combined with techniques like microwave ablation or drug-eluting beads to release tumor-specific antigens. The approach aims to stimulate the immune system to target and kill cancer cells more effectively. Participants will receive either the CpG-ODN injection alone or in combination with CAR-T cells that target the OX40 receptor. The study will assess both the side effects and the therapeutic efficacy of these combined treatments.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Solid advanced malignant tumors
* Age between18 and 80 years
* Life expectancy is greater than three months

Exclusion Criteria:

* Benign tumor
* Life expectancy is less than three months
* Serious medical comorbidity
* Others

Where it's running

• The Second Affiliated Hospital of Guangzhou Medical University
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Principal investigator: Zhenfeng Zhang, MD, PhD — Second Affiliated Hospital of Guangzhou Medical University
• Study coordinator: Zhenfeng Zhang, MD, PhD
• Email: zhangzhf@gzhmu.edu.cn
• Phone: +862039195966

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• 68Ga-SorB PET/CT imaging for solid tumors

  This study tests a new PET tracer called 68Ga-SorB to see if it can safely and accurately detect tumors in adults with melanoma, liver, lung, breast, pancreatic, ovarian cancer, or cholangiocarcinoma.

  Recruiting Peking University Third Hospital · Beijing, Beijing Municipality · NCT07760012

• First-in-human test of HH160 in people with advanced solid tumors

  HH160 is being tested to see if it is safe and how it behaves in the body, to see if it has early signs of helping various advanced cancers in adults.

  Recruiting at 3 sites Phase 1 Huahui Health · Waratah, New South Wales and 2 other locations · NCT07623369

• IDOV-Immune for advanced solid tumors

  This trial will try a single IV infusion of an engineered oncolytic vaccinia virus called IDOV-Immune in adults with advanced solid tumors that no longer respond to standard treatments.

  Recruiting at 5 sites Phase 1 ViroMissile, Inc. · St Louis, Missouri and 4 other locations · NCT06910657

• ImmunoPET imaging for solid tumors targeting Trop2

  This study is testing a new imaging method to see if it can help diagnose solid tumors like bladder and prostate cancer better than current methods.

  Recruiting Phase 2/3 RenJi Hospital · Shanghai · NCT06851663

• Testing TNG456 and Abemaciclib in Patients with Solid Tumors Lacking MTAP

  This study is testing a new drug called TNG456, alone and with another drug called abemaciclib, to see if it helps people with advanced solid tumors that have lost a specific gene called MTAP.

  Recruiting at 15 sites Phase 1/2 Tango Therapeutics, Inc. · Scottsdale, Arizona and 14 other locations · NCT06810544

• Using brodalumab to treat immune-related side effects from cancer therapy

  This study is testing if brodalumab can help cancer patients who are having immune-related side effects from their immunotherapy treatment feel better.

  Recruiting Phase 1 Columbia University · New York, New York · NCT06673329

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.